Tag: DUX4
-
Epicrispr Raises $90 Million to Silence Disease Genes Without Cutting DNA
Epicrispr raised $90 million to advance EPI-321, a single-dose AAV therapy designed to silence DUX4 without permanently editing DNA.
Epicrispr raised $90 million to advance EPI-321, a single-dose AAV therapy designed to silence DUX4 without permanently editing DNA.